In order to ensure the ongoing safety of our patients and staff, please note that CAMH is maintaining the requirement for universal masking of staff, patients, visitors/essential care partners, contractors/vendors at CAMH. A hospital-approved mask will be required to enter into our buildings and in all common areas. Further, current screening stations and protocols are also being maintained and there will be no change in the requirement for anyone with COVID-19 symptoms or exposure risks to not enter the hospital.
Research in the Schizophrenia Division is broad and includes studies on improving therapeutic and assessment approaches, management of side effects, enhancing patient recovery, as well identifying risk factors and causes to intervene early and develop new treatments. Our core research faculty has diverse interests and expertise in clinical treatment trials, metabolic risks, psychopharmacology, virtual reality, genetics and pharmacogenetics, neuropsychology, brain physiology and imaging, molecular biology and neuroinformatics. Together, we have created a research program that exemplifies a modern, translational approach to research on schizophrenia with the aim of better understanding, treating and preventing schizophrenia.
Research Areas & Projects
Current projects and key areas of research in the Schizophrenia Clinical Division include:
Metabolic risk management
Genetics and pharmacogenetics
Youth psychosis and at-risk populations
Recovery and rehabilitation
Visit our Programs & Services Directory for information on clinical care, including youth psychosis prevention, early psychosis, inpatient and outpatient services and more.